1. Chemoembolization Alone or Associated With Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study.
- Author
-
Fiorentini G, Sarti D, Nardella M, Inchingolo R, Nestola M, Rebonato A, and Guadagni S
- Subjects
- Aged, Antineoplastic Agents, Immunological therapeutic use, Colorectal Neoplasms pathology, Female, Humans, Irinotecan administration & dosage, Kaplan-Meier Estimate, Liver Neoplasms secondary, Male, Middle Aged, Prospective Studies, Topoisomerase I Inhibitors administration & dosage, Treatment Outcome, Bevacizumab therapeutic use, Chemoembolization, Therapeutic methods, Colorectal Neoplasms therapy, Liver Neoplasms therapy
- Abstract
Aim: to assess efficacy and safety of chemoembolization alone (TACE) and followed by bevacizumab (TACE-B) in patients with colorectal liver metastases (CRC-LM) (NCT03732235)., Patients and Methods: The study included 30 consecutive patients with CRC-LM. They were informed about the types of treatment available: TACE with irinotecan loaded into polythylene glycol embolics alone or followed by bevacizumab therapy. Each patient underwent self-randomization and 17 chose TACE, whereas 13 chose TACE-B., Results: Tumor response at 3 months was complete response in one (6%) and four (31%) patients, and partial response in two (13%) and six (46%) patients, after TACE and TACE-B, respectively. No complications were observed during TACE. Most TACE-related adverse events were correlated with post-embolic syndrome., Conclusion: The preliminary results of the study showed that the TACE-B is feasible and tolerable. This study will be continued in order accrue a larger number of patients and longer follow-up., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF